The CNBX chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the CNBX chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The CNBX stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View CNBX Detailed Price Forecast - CNN Money||View CNBX Detailed Summary - Google Finance|
|View CNBX Detailed Summary - Yahoo! Finance||View CNBX Stock Research & Analysis - Zacks.com|
|View CNBX Trends & Analysis - Trade-Ideas||View CNBX Major Holders - Barrons|
|View CNBX Call Transcripts - NASDAQ||View CNBX Breaking News & Analysis - Seeking Alpha|
|View CNBX Annual Report - CompanySpotlight.com||View CNBX OTC Short Report - OTCShortReport.com|
|View CNBX Fundamentals - TradeKing||View CNBX SEC Filings - Bar Chart|
|View Historical Prices for CNBX - The WSJ||View Performance/Total Return for CNBX - Morningstar|
|View the Analyst Estimates for CNBX - MarketWatch||View the Earnings History for CNBX - CNBC|
|View the CNBX Earnings - StockMarketWatch||View CNBX Buy or Sell Recommendations - MacroAxis|
|View the CNBX Bullish Patterns - American Bulls||View CNBX Short Pain Metrics - ShortPainBot.com|
|View CNBX Stock Mentions - StockTwits||View CNBX Stock Mentions - PennyStockTweets|
|View CNBX Stock Mentions - Twitter||View CNBX Investment Forum News - Investor Hub|
|View CNBX Stock Mentions - Yahoo! Message Board||View CNBX Stock Mentions - Seeking Alpha|
|View Insider Transactions for CNBX - SECform4.com||View Insider Transactions for CNBX - Insider Cow|
|View CNBX Major Holdings Summary - CNBC||View Insider Disclosure for CNBX - OTC Markets|
|View Insider Transactions for CNBX - Yahoo! Finance||View Institutional Holdings for CNBX - NASDAQ|
|View CNBX Stock Insight & Charts - FinViz.com||View CNBX Investment Charts - StockCharts.com|
|View CNBX Stock Overview & Charts - BarChart||View CNBX User Generated Charts - Trading View|
Cannabics Pharmaceuticals' in-vivo Tumor Inhibitory Effect Study Concludes with a Statistical Significance of p ≤ 0.016
Posted on Wednesday February 17, 2021
Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, further clarifies with regards to the final study results released on February 16, 2021, that said study results showing "a significant and robust inhibitory effect on tumor growth, as evidenced by a 33% reduction in tumor volume in mice exposed to RCC-33 in comparison with sham control mice," are said to have statistical significance with p ≤ 0.016.
Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, has just released the final results of its in-vivo study evaluating the efficacy of the company's proprietary drug candidate RCC-33 for the treatment of colorectal cancer in nude-mice. The final study results demonstrate a significant and robust inhibitory effect on tumor growth, as evidenced by a 33% reduction in tumor volume in mice exposed to RCC-33 in comparison with sham control mice (p £ 0.016).
Cannabics Pharmaceutical's Interim in-vivo Study Results Show a 27% Lower Tumor Volume in Mice Treated with Company's Proprietary Drug Candidate for Colorectal Cancer
Posted on Wednesday February 03, 2021
Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicines, announced today that it has obtained interim results for its ongoing in-vivo study evaluating the efficacy of the company's proprietary drug candidate RCC-33 for colorectal cancer in nude-mice. The interim results show a 27% reduction in tumor volume in mice exposed to RCC-33 in comparison with sham control mice. Both groups were inoculated with colorectal cancer cells. Daily doses of intraperitoneal (IP) delivery of RCC-33 or sham were initiated on day 5. Differences in tumor volume between the two groups were first observed after 5 days of treatment (day 10). Interim results of a 27% reduction in tumor volume were recorded after 12 days of treatment (day 17), with p-value=0.022. Study is ongoing.
Cannabics Pharmaceuticals Initiates In-Vivo Animal Studies for FDA Pre-IND Meeting Package
Posted on Monday December 21, 2020
Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based therapeutic formulations and medicines, announced today that it has initiated a series of proof of concept (POC), in-vivo, animal model studies to test its drug candidate RCC-33 on mice transplanted with colorectal cancer tumor cell lines. Study results are to be included in the data package being prepared for submission to the US Food and Drug Administration along with a request for a pre-IND Meeting.